Literature DB >> 6211136

Moxalactam penetration into cerebrospinal fluid in patients with bacterial meningitis.

J Modai, M Wolff, J Lebas, A Meulemans, C Manuel.   

Abstract

Penetration of moxalactam into the cerebrospinal fluid was studied in 11 patients with bacterial meningitis undergoing treatment with other antibiotics. Moxalactam at a dose of 20 mg/kg was administered as three 30- to 45- min infusions at 8-h intervals, once between days 2 and 4 and a second time between days 11 and 20 of treatment with the other antibiotics. Serum and cerebrospinal fluid were sampled 60, 90, or 120 min after the third moxalactam dose for measurement of the concentration of this drug by high-performance liquid chromatography. The concentration of moxalactam in cerebrospinal fluid ranged from 1.5 to 11 micrograms/ml, depending on the sampling time and the time elapsed since the onset of the disease. These concentrations in cerebrospinal fluid were equal to or higher than the minimum inhibitor concentrations for Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), and most of the gram-negative bacilli except for Pseudomonas aeruginosa. These results show that moxalactam has good penetrability when the meninges are inflamed and that it might be considered in cases of bacterial meningitis when the susceptibility of the pathogen indicates its usefulness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6211136      PMCID: PMC181939          DOI: 10.1128/AAC.21.4.551

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.

Authors:  S H Landesman; M L Corrado; C C Cherubin; M Gombert; D Cleri
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965

2.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

3.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

4.  Treatment of experimental Haemophilus influenzae type b meningitis with 1-oxa-beta-lactam (LY127935).

Authors:  C S Cordera; R S Pekarek
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

Authors:  S L Kaplan; E O Mason; H Garcia; S J Kvernland; E M Loiselle; D C Anderson; A A Mintz; R D Feigin
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

6.  Determination of moxalactam in human body fluids by liquid chromatographic and microbiological methods.

Authors:  D J Miner; D L Coleman; A M Shepherd; T C Hardin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

7.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

  7 in total
  7 in total

1.  Susceptibility studies of multiply resistant Haemophilus influenzae isolated from pediatric patients and contacts.

Authors:  J Campos; S Garcia-Tornel; I Sanfeliu
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

2.  Treatment of bacterial meningitis.

Authors:  H P Lambert
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

Review 3.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Concentrations of cefoperazone in cerebrospinal fluid during bacterial meningitis.

Authors:  D Cable; G Overturf; G Edralin
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

Review 5.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

6.  Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.

Authors:  R H Eng; C Cherubin; S M Smith; F Buccini
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 7.  Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.